Ubichem gains approval to supply cGMP radiolabelled API

By Nick Taylor

- Last updated on GMT

Related tags: European union

Hungary-based Ubichem Research has gained approval to supply cGMP radiolabelled APIs in the European Union (EU), positioning it to benefit from increased demand.

The rise of microdosing has increased interest in radiolabelled compounds, prompting companies including PerkinElmer to bolster capabilities. Ubichem gained radiochemical capabilities through an acquisition in 2007 and since then has worked to enhance its offering.

József Répási, managing director of Ubichem, explained to Outsourcing-Pharma that the latest step in these efforts has been the expansion of current good manufacturing practices (cGMP) to the radiolabelling laboratories.

Equipment has been upgraded and installed to give the Ubichem isotope sysnethis group, which has extensive experience working with radiolabelled compounds, a site that is in compliance with cGMP.

Having taken these steps Ubichem had the site inspected by Hungarian authorities for the production of radiolabelled cGMP active pharmaceutical ingredients (API). Répási commented that the site has also been successfully audited by a client.

An agreement between the Hungarian authorities and the EU means the approval allows Ubichem to supply the European market. Répási said that there has been a definite increase in demand for radiolabelled APIs and Ubichem is now well equipped to serve this growth market.

Shipping

The shelf-life of radiolabelled APIs poses difficulties for shipping. To overcome these challenges Ubichem has outsourced shipping to a specialist company with more than 20 years of experience in the radiochemistry sector.

Répási explained that packaging compliant with API and radiolabelling guidelines is used. The radiolabelled APIs are then in shipped in dry ice at -78ºC to maximise shelf life.

Ubichem has sought to ship radiolabelled APIs to the US but the compounds’ shelf-life has limited penetration into the lucrative market, added Répási. Also, there is significant competition from US-based radiolabelled API producers. Japan also represents an opportunity.

Related news

Related products

show more

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

QPS: Global Custom-Built Research Services

QPS: Global Custom-Built Research Services

QPS | 16-Dec-2019 | Product Brochure

Performing complex studies in special populations with remarkable agility. Clinical research just got better with QPS’ Custom-Built Research Services....

Related suppliers

Follow us

Products

View more

Webinars